- Dosage: Dihydroartemisinin 40mg, Piperaquine 320mg
- Packaging: 10tablets/blister*10/box
- Shelf Life: 36months
Package:
Product Description
Dihydroartemisinin 40mg + Piperaquine 320mg Tablets: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
Before Dihydroartemisinin 40mg + Piperaquine 320mg Tablets is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
Each point above is reproduced because it has a practical consequence for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — Supply Parameters
| Product Name | Dihydroartemisinin + Piperaquine Tablets (Dihydroartemisinin 40mg + Piperaquine 320mg Oral Tablets) |
| Specification | Each tablet contains: Dihydroartemisinin 40mg + Piperaquine 320mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredients | Dihydroartemisinin / Piperaquine |
| Pharmacological Class | Antimalarial Combination (Artemisinin Derivative / 4-Aminoquinoline Derivative) |
| Route of Administration | Oral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Once daily for 3 consecutive days. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.
Quality Control, Pharmacopoeial Standards & Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
A typical release panel for this presentation covers:
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
- Testing for packaging integrity and seal testing
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packaging, Labelling & Export
- Pack size: Blister pack (PVC-Alu) or strip pack, typically per 3-day treatment course. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Registration, Dossier & Tender Support
The legal manufacturer named on every document for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
Dihydroartemisinin 40mg + Piperaquine 320mg Tablets is presented here against ACT regimens named in the WHO Model List of Essential Medicines. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Frequently Asked Questions
What pack size is available for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets?
Standard commercial packaging for this line is Blister pack (PVC-Alu) or strip pack, typically per 3-day treatment course. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Dihydroartemisinin 40mg + Piperaquine 320mg Tablets?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
What is the difference between artesunate and artemether for injection?
Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Related Malaria & ACTs Products
- Chloroquine Phosphate 500mg Tablets — 500mg
- Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg — 175mg
- Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg — 175mg
- Artesunate 200mg + Amodiaquine 600mg Tablets — 200mg
- Artesunate 400mg Mefloquine 500mg Tablets — 400mg
- Artemether Lumefantrine 80/480mg Tablets — 80mg
Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.
Request a Quotation for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets
Tell us the monograph, pack size and quantity required for Dihydroartemisinin 40mg + Piperaquine 320mg Tablets 40mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO — Malaria case management: operations manual
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
